Literature DB >> 19656658

Correlation of prepulse inhibition and Wisconsin Card Sorting Test in schizophrenia and controls: effects of smoking status.

Rachel A Rabin1, Kristi A Sacco, Tony P George.   

Abstract

BACKGROUND: In schizophrenia, neurocognitive deficits associated with the illness are modulated by tobacco smoking. However, little is known about how smoking status modulates the relationships between neurocognitive measures in schizophrenia and healthy control subjects.
OBJECTIVE: The goal of this study was to evaluate the relationship between sensorimotor gating assessed by prepulse inhibition (PPI) and executive cognitive function using the Wisconsin Card Sorting Test (WCST) in schizophrenia and controls as a function of smoking status.
METHOD: We studied PPI and neuropsychological function in four groups (N=50); smokers with schizophrenia (SS; n=15), control smokers (CS; n=13), non-smokers with schizophrenia (SNS; n=11) and control non-smokers (CNS; n=11).
RESULTS: SNS demonstrated the poorest PPI, while SS showed comparably high levels of PPI to CNS. Non-psychiatric controls outperformed patients on WCST outcomes irrespective of smoking status. Several prefrontal outcome measures on the WCST (categories completed, percentage perseverative and non-perseverative errors) correlated significantly with PPI at the 60 and 120 ms prepulse intervals. In contrast, there were no significant correlations between PPI and any WCST outcomes in SNS, CS or CNS, and few significant correlations between PPI and other neuropsychological measures. DISCUSSION: Our preliminary data suggests that the correlation between sensorimotor gating (PPI) and prefrontal executive cognitive functioning (WCST) is enhanced by acute cigarette smoking in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19656658      PMCID: PMC2752975          DOI: 10.1016/j.schres.2009.07.006

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  36 in total

Review 1.  Nicotine use in schizophrenia: the self medication hypotheses.

Authors:  Veena Kumari; Peggy Postma
Journal:  Neurosci Biobehav Rev       Date:  2005       Impact factor: 8.989

2.  Structural brain correlates of prepulse inhibition of the acoustic startle response in healthy humans.

Authors:  Veena Kumari; Elena Antonova; Elizabeth Zachariah; Adrian Galea; Ingrid Aasen; Ulrich Ettinger; Martina T Mitterschiffthaler; Tonmoy Sharma
Journal:  Neuroimage       Date:  2005-04-07       Impact factor: 6.556

3.  Effects of atomoxetine on cognitive function and cigarette smoking in schizophrenia.

Authors:  Kristi A Sacco; Cerissa Creeden; Erin L Reutenauer; Jennifer C Vessicchio; Andrea H Weinberger; Tony P George
Journal:  Schizophr Res       Date:  2008-11-07       Impact factor: 4.939

4.  Word and tone working memory deficits in schizophrenia.

Authors:  B E Wexler; A A Stevens; A A Bowers; M J Sernyak; P S Goldman-Rakic
Journal:  Arch Gen Psychiatry       Date:  1998-12

5.  Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms.

Authors:  Kristi A Sacco; Angelo Termine; Aisha Seyal; Melissa M Dudas; Jennifer C Vessicchio; Suchitra Krishnan-Sarin; Peter I Jatlow; Bruce E Wexler; Tony P George
Journal:  Arch Gen Psychiatry       Date:  2005-06

Review 6.  Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies.

Authors:  D L Braff; M A Geyer; N R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

7.  Contrasting cortical and subcortical activations produced by attentional-set shifting and reversal learning in humans.

Authors:  R D Rogers; T C Andrews; P M Grasby; D J Brooks; T W Robbins
Journal:  J Cogn Neurosci       Date:  2000-01       Impact factor: 3.225

8.  Effects of nicotine on cognitive deficits in schizophrenia.

Authors:  Josette G Harris; Susan Kongs; Diana Allensworth; Laura Martin; Jason Tregellas; Bernadette Sullivan; Gary Zerbe; Robert Freedman
Journal:  Neuropsychopharmacology       Date:  2004-07       Impact factor: 7.853

9.  A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia.

Authors:  R S Keefe; S E Roitman; P D Harvey; C S Blum; R L DuPre; D M Prieto; M Davidson; K L Davis
Journal:  Schizophr Res       Date:  1995-09       Impact factor: 4.939

10.  Frontal/executive impairments in schizophrenia.

Authors:  R Morice; A Delahunty
Journal:  Schizophr Bull       Date:  1996       Impact factor: 9.306

View more
  18 in total

Review 1.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

2.  Deficient prepulse inhibition in schizophrenia detected by the multi-site COGS.

Authors:  Neal R Swerdlow; Gregory A Light; Joyce Sprock; Monica E Calkins; Michael F Green; Tiffany A Greenwood; Raquel E Gur; Ruben C Gur; Laura C Lazzeroni; Keith H Nuechterlein; Allen D Radant; Amrita Ray; Larry J Seidman; Larry J Siever; Jeremy M Silverman; William S Stone; Catherine A Sugar; Debby W Tsuang; Ming T Tsuang; Bruce I Turetsky; David L Braff
Journal:  Schizophr Res       Date:  2014-01-07       Impact factor: 4.939

3.  Effects of the nicotinic α7 receptor partial agonist GTS-21 on NMDA-glutamatergic receptor related deficits in sensorimotor gating and recognition memory in rats.

Authors:  Patrick M Callahan; Alvin V Terry; Ashok Tehim
Journal:  Psychopharmacology (Berl)       Date:  2014-03-05       Impact factor: 4.530

4.  Loss-of-function mutation in Mirta22/Emc10 rescues specific schizophrenia-related phenotypes in a mouse model of the 22q11.2 deletion.

Authors:  Anastasia Diamantopoulou; Ziyi Sun; Jun Mukai; Bin Xu; Karine Fenelon; Maria Karayiorgou; Joseph A Gogos
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-10       Impact factor: 11.205

5.  Age-associated improvements in cross-modal prepulse inhibition in mice.

Authors:  Jared W Young; Chelsea K Wallace; Mark A Geyer; Victoria B Risbrough
Journal:  Behav Neurosci       Date:  2010-02       Impact factor: 1.912

Review 6.  Epigenetics and biomarkers in the staging of neuropsychiatric disorders.

Authors:  Trevor Archer; Richard J Beninger; Tomas Palomo; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2010-03-17       Impact factor: 3.911

7.  Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial.

Authors:  Joo-Cheol Shim; Do-Un Jung; Sung-Soo Jung; Young-Soo Seo; Deuk-Man Cho; Ji-Heon Lee; Sae-Woom Lee; Bo-Geum Kong; Je-Wook Kang; Min-Kyung Oh; Sang-Duk Kim; Robert P McMahon; Deanna L Kelly
Journal:  Neuropsychopharmacology       Date:  2011-11-02       Impact factor: 7.853

8.  The relationship between acoustic startle response measures and cognitive functions in Japanese patients with schizophrenia.

Authors:  Taro Kishi; Yasuhisa Fukuo; Tomo Okochi; Kunihiro Kawashima; Masatsugu Moriwaki; Osamu Furukawa; Kiyoshi Fujita; Giovanna M Musso; Christoph U Correll; John M Kane; Nakao Iwata
Journal:  Neuromolecular Med       Date:  2012-03-28       Impact factor: 3.843

9.  Prepulse inhibition in HIV-associated neurocognitive disorders.

Authors:  Arpi Minassian; Brook L Henry; Steven Paul Woods; Florin Vaida; Igor Grant; Mark A Geyer; William Perry
Journal:  J Int Neuropsychol Soc       Date:  2013-04-03       Impact factor: 2.892

Review 10.  Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders.

Authors:  Alvin V Terry; Patrick M Callahan; Caterina M Hernandez
Journal:  Biochem Pharmacol       Date:  2015-07-29       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.